The disclosure provides compositions and dosage forms for promoting healthy microbial flora in a mammal, for example, a human. The disclosure further provides compositions and dosage forms for disrupting biofilm or preventing formation of biofilm containing pathogenic bacteria and/or pathogenic fungi in a particular region of a subject. The dosage forms contain (i) an isolated non-pathogenic fungal strain that is viable in the region of the subject, (ii) an isolated non-pathogenic bacterial strain that is viable in the region of the subject, and optionally (iii) an enzyme capable of disrupting the biofilm. The present disclosure also provides methods of disrupting a biofilm or preventing formation of a biofilm with such a composition or dosage form, methods of identifying a subject suitable for treatment with such a composition or dosage form, and methods of improving nutrient absorption using such a composition or dosage form.

This invention relates to use of a strain of lactic acid bacteria for inhibiting the growth of methane-producing bacteria and/or archaea in the gastrointestinal tract of monogastric animals, reducing the ability of the microbiome of the gastrointestinal tract to produce methane, reducing methane production or emissions, and/or for improving feed efficiency, and/or body weight or body composition of a monogastric animal.

The probiotic composition comprises at least one lactic acid bacteria strain, preferably Lactobacillus with intestinal tropism, for use in promoting juvenile growth in livestock, with stimulation of linear growth and/or of IGF-1 level. Exemplary lactic acid bacteria include Lactobacillus plantarum, Lactobacillus fermentum, Lactobacillus casei, Lactobacillus paracasei and Lactobacillus rhamnosus. The strains can be selected in a mouse model. The invention also relates to a probiotic treatment method using this composition.

Disclosed herein are methods for improving gastrointestinal barrier function, alleviating a gastrointestinal barrier dysfunction-associated disorder, and inhibiting growth of enteric pathogenic bacteria using a composition containing Lactobacillus rhamnosus MP108, Bifidobacterium longum subsp. infantis BLI-02, and Bifidobacterium animalis subsp. lactis BB-115, which are deposited at the China General Microbiological Culture Collection Center (CGMCC) respectively under accession numbers CGMCC 21225, CGMCC 15212, and CGMCC 21840. A number ratio of Lactobacillus rhamnosus MP108, Bifidobacterium longum subsp. infantis BLI-02, and Bifidobacterium animalis subsp. lactis BB-115 ranges from 1:0.2:0.67 to 1:9:9.

The application discloses Lactobacillus strains having a beneficial effect on the metabolic health on a mammalian subject. Further disclosed is compositions comprising such strains and the use thereof for improving the metabolic health or for lowering the blood glucose level in a mammalian subject.

The application discloses Lactobacillus strains having a beneficial effect on the metabolic health on a mammalian subject. Further disclosed is compositions comprising such strains and the use thereof for improving the metabolic health or for lowering the blood glucose level in a mammalian subject.

The present invention is intended for the use of a probiotic composition comprising Bifidobacterium animalis subs. lactis (B. lactis), Bifidobacterium longum and Lactobacillus rhamnosus, in particular the strains B. lactis CECT 8145, B. longum ES1 CECT 7347 and/or L. rhamnosus CECT 8361, in the treatment and/or prevention of psoriasis outbreaks or psoriasis.

A composition is used for prevention or treatment of bacterial vaginosis (BV) and regulation of vaginal immunity and said composition with effective amount is selected from the groups comprising Lactobacillus rhamnosus GMNL-680 and Lactobacillus plantarum GMNL-682; the composition of the present invention is used to prevent and treat bacterial vaginosis by inhibition of the growth of pathogens and regulation of the expression of immunoregulators and is prepared in the forms of pharmaceutical compositions, food or other combinations thereof.

The present invention relates to a composition in powder form comprising probiotic bacteria and at least one iron-milk protein complex. Such iron-milk protein complex advantageously does not cause significant reduction in the viability of the bacteria and thus such iron source is advantageously used to fortify a composition in powder form comprising probiotic bacteria.

Disclosed are date palm compositions and methods of use of such compositions. Such compositions may be used as part of a growth medium for culture of microorganisms. In certain embodiments, date palm extracts of the disclosure are used as part a culture medium to grow Lactobacilli.